Related Experiment Video
Updated: Mar 18, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
Published on: January 20, 2023
Heat Shock Protein 70s as Potential Molecular Targets for Colon Cancer Therapeutics
Jennifer D Black, Khosrow Rezvani1
1Division of Basic Biomedical Sciences, Sanford School of Medicine, The University of South Dakota, 414 E. Clark Street, Lee Medical Building, Vermillion, SD 57069, USA. khosrow.rezvani@usd.edu.
Background:
Targeted drugs modulate selective pathways activated or repressed only in cancer cells, resulting in a higher response to chemotherapy with less severe side effects. The use of a selected member of the heat shock protein 70 family (HSP70) as an effective therapeutic target in the treatment of colorectal cancer (CRC) will be the focus of this review.
Methods:
We generated two main questions for this study: 1) What are the current and potential future molecular therapies in CRC? 2) Can selective members of the HSP70 family advance drug design and drug discovery for treatment of CRC patients? We discuss related articles based on their significance and translational contributions to the existing literature.
Results:
The first part of this review discusses molecularly targeted agents that are currently used successfully in the clinic for the treatment of patients with CRC and highlights several novel targeted agents that are being investigated in ongoing trials. The second part of this review focuses on the unique tumorigenic functions of heat shock proteins, particularly mortalin-2, an essential heat shock protein for mitochondrial biogenesis in normal cells and a dominant oncoprotein in colon cancer cells. Basic and clinical studies have justified mortalin-2 as a potential molecular target, and its inhibition could dramatically improve patients' responses to standard chemotherapies.
Conclusion:
Further understanding of the contributions of HSP70 family members to CRC at the molecular level, combined with translation of new concepts into effective targeted therapies, are anticipated to improve clinical outcomes and increase the therapeutic synergy with combination treatment with cytotoxic agents.
Insights
Targeting heat shock protein 70 (HSP70) family members, particularly mortalin-2, shows promise for colorectal cancer (CRC) treatment. Inhibiting mortalin-2 may enhance chemotherapy effectiveness and improve patient outcomes.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Targeted therapies offer improved chemotherapy response with fewer side effects.
- Heat shock protein 70 (HSP70) family members are explored as therapeutic targets in colorectal cancer (CRC).
Purpose of the Study:
- To review current and future molecular therapies for CRC.
- To assess the potential of HSP70 family members in advancing CRC drug design and discovery.
Main Methods:
- Literature review focusing on significant and translational contributions.
- Analysis of current clinical and investigational CRC targeted agents.
- Examination of HSP70 family's tumorigenic functions, specifically mortalin-2.
Main Results:
- Current targeted agents and novel investigational therapies for CRC are discussed.
- Mortalin-2, crucial for mitochondrial biogenesis, acts as an oncoprotein in colon cancer.
- Mortalin-2 inhibition is identified as a potential strategy to enhance patient response to chemotherapy.
Conclusions:
- Further research into HSP70 family's role in CRC is needed.
- Translating molecular insights into targeted therapies can improve clinical outcomes.
- Targeting HSP70 family members may offer therapeutic synergy with cytotoxic agents.
Related Concept Videos
Targeted Cancer Therapies
There are several types of targeted therapies against...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Molecular Chaperones and Protein Folding
The...

